Free access
Letters
8 December 2020

COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient SettingsFREE

Publication: Annals of Internal Medicine
Volume 174, Number 5
Background: Coronavirus disease 2019 (COVID-19) has spread, causing a worldwide pandemic, and prolonged effects are emerging (1, 2). The term “long COVID” describes illness in persons who continue to report lasting effects after infection (3, 4). To date, little information exists about outpatient settings in this novel disease where 81% of cases are reportedly on the mild end of the spectrum (5). Informing patients and physicians about COVID-19 symptom evolution may help them recognize the time course of the disease, legitimize patients' concerns, and reassure them when possible. Messages around potentially persisting symptoms could also assist in reinforcing public health measures to avoid the spread of infection.
Objective: To describe COVID-19 symptom evolution and persistence in an outpatient setting in Geneva, Switzerland, from day 1 through day 30 to 45 after diagnosis.
Methods: From 18 March to 15 May 2020, the Geneva University Hospitals (sole and largest public hospital in Geneva) was 1 of 5 available testing centers and served more than 50% of patients with COVID-19 in the Geneva canton. Only symptomatic persons were tested during that period. Because many practices were closed, persons who were not hospitalized at baseline could benefit from remote follow-up with an ambulatory care center (a process called COVICARE) in case their primary care physician was unavailable for follow-up care (a full description is available at www.covicare24.com). Exclusion criteria were refusal to provide consent and administrative reasons (living outside the Geneva canton).
Most patients were called every 48 hours for the first 10 days with a standardized interview inquiring about self-reported symptoms (Supplement). Follow-up during the 10 days was suspended if patients declined follow-up, clinically recovered, or were hospitalized (Figure 1). Participants were called every 24 hours if they reported deteriorating clinical symptoms; those who were unreachable (eligible minus reached) were called again the next day. All patients were then contacted again 30 to 45 days after diagnosis. To address the varying frequency of contacts during the first 10 days, we combined assessments into 2-day intervals: days 1 to 2 through days 9 to 10. When 2 measurements were available, we included only the first observation per assessment interval.
Figure 1. Study flow diagram.
Out of the initial cohort of 703 participants, 669 ambulatory patients were ultimately included, excluding those who declined to participate (n = 31) or who lived outside the Geneva canton (n = 3). Reasons to suspend follow-up during the first 10 d were clinical recovery (≥10 d from symptom onset and 48 h without symptoms), patient wish, or hospitalization during follow-up. Attempts were made to assess all 669 participants at day 30–45 from diagnosis.
Findings: Of 30 557 persons tested in Geneva during the study period, 18.1% tested positive (n = 5534); 22.2% of these were hospitalized (n = 1229), and 703 enrolled in COVICARE follow-up. Out of the initial cohort, 669 persons were ultimately included (Figure 1). The mean age was 42.8 years (SD, 13.7); 60% of included patients were women, 24.6% were health care workers, and 68.8% had no underlying risk factors. Forty participants were hospitalized during the study period. We included their data when available (up to hospitalization and again at day 30 to 45). Hospitalized patients were significantly older (mean age, 53.2 years [SD, 11.7]); 55% were male, 12.5% were health care workers, and 62.5% had underlying risk factors.
Figure 2 presents the proportion of the 669 patients with various symptoms over time. Cough and loss of taste or smell were common early in the clinical course. At 30 to 45 days (mean, 43 days) from diagnosis, at least 32% of the 669 originally included patients reported 1 or more symptoms. Fatigue, dyspnea, and loss of taste or smell were the main persistent symptoms. Participants not reached between days 30 and 45 (n = 159) had similar characteristics to those reached in that period (mean age, 41.8 years [SD, 14.8]; 58% were female, 25.9% were health care workers, and 67.9% had no risk factors).
Figure 2. Longitudinal evolution of COVID-19 symptoms in outpatient settings (n = 669).
Forty of the participants were hospitalized during follow-up. Their data were included in the reported symptoms when available (up to hospitalization and again at day 30–45). COVID-19 = coronavirus disease 2019.
Discussion: Coronavirus disease 2019 can persist and result in prolonged illness. Our study shows persistence of symptoms in a third of ambulatory patients 30 to 45 days after diagnosis even if we assume that those lost to follow-up were all asymptomatic. Fatigue, dyspnea, and loss of taste or smell were the main persistent symptoms. These results are in line with a recent study of 274 participants that reported the persistence of symptoms 14 to 21 days after diagnosis (2).
Our study has several limitations, including missing data and ascertainment bias at each assessment interval. Baseline characteristics were similar overall between participants reached and not reached on day 30 to 45.
In conclusion, this study shows that patients with COVID-19 develop an array of symptoms that evolve over time. Recognizing the persistence of symptoms could legitimize patients' concerns in an unknown and new disease. Adequate communication can provide reassurance, reduce anxiety, and potentially optimize recovery.

Appendix: Members of the COVICARE TEAM

Members of the COVICARE TEAM who authored this work: Mayssam Nehme, Olivia Braillard, and Delphine Courvoisier (Geneva University Hospitals, Geneva, Switzerland); Gabriel Alcoba (Geneva University Hospitals and Médecins Sans Frontières, Geneva, Switzerland); Idris Guessous and François Chappuis (Geneva University Hospitals and University of Geneva, Geneva, Switzerland); and Sigiriya Aebischer Perone (Geneva University Hospitals and International Committee of the Red Cross, Geneva, Switzerland).
Members of the COVICARE TEAM who contributed to this work but did not author it: Marwene Grira, Giovanni Innaurato, Jennifer Socquet, Chloé Chevallier-Lugon, Luisa Carnino, Bruno Lab, Jose Sandoval, Silvia Stringhini, Pierre Chopard, Flora Koegler, and Dan Lebowitz (Geneva University Hospitals, Geneva, Switzerland); Simon Regard and Aglaé Tardin (Cantonal Health Service, General Directorate for Health, Geneva, Switzerland); and Camille Genecand (Cantonal Health Service, General Directorate for Health, and Geneva University Hospitals, Geneva, Switzerland).

Supplemental Material

Supplement. Survey Data Collected

References

1.
Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603-605. [ 32644129] doi: 10.1001/jama.2020.12603
2.
Tenforde MW, Kim SS, Lindsell CJ, et al; IVY Network Investigators. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network — United States, March–June 2020. MMWR Morb Mortal Wkly Rep. 2020;69:993-998. [ 32730238] doi: 10.15585/mmwr.mm6930e1
3.
Mahase E. Covid-19: What do we know about “long covid”. BMJ. 2020;370:m2815. [ 32665317] doi: 10.1136/bmj.m2815
4.
Crosby SS. My COVID-19. Ann Intern Med. 2021;174:120-1. [ 32777184] doi: 10.7326/M20-5126
5.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239-1242. [ 32091533] doi: 10.1001/jama.2020.2648

Comments

0 Comments
Sign In to Submit A Comment
Anna Strek4 January 2021
Is persistent fatigue symptom during and post SARS-CoV-2 infection connected with HHV-6?

To the Editor,

Not only is fatigue common among all symptoms in COVID-19 (according to data from COVID Symptom Study mobile app about one fourth of users complaining from one or more symptoms indicated fatigue [1]), but also its lingering impact is becoming apparent. The latter fact is confirmed by Nehme and colleagues in the letter published online in Annals [2], where they report that after weeks-long recovery slightly less than 15 % of patients still complained of fatigue. This long-lasting trend in symptom manifestation reported by Nehme is confirmed by other studies to an even considerably greater extent: 54 % [3].

Authors of [2] conclude that consciousness of symptoms’ coexistence and duration could be an important factor in reducing patients’ anxiety and helping their recovery. I could not agree more and I find their report as one of the steps bringing the SARS-CoV-2 infection treatment forward. Yet at the same time it brings closer two big questions: how does the coronavirus cause fatigue and how to help patients suffering from it?

On the other hand, a disease called chronic fatigue syndrome (CFS) manifests itself with long-lasting fatigue. The causes of CFS are partially recognized, one of them is viral infection with HHV-6 [4] (also other viruses e.g. HIV may cause fatigue). Authors of [4] report research results of others and their own according to which 53 – 86 % patients with CFS had elevated antibody titres to the herpesvirus. Having in mind how widespread HHV-6 is, Eymard and colleagues conclude that reactivation of latent herpesvirus “would seem an attractive hypothesis to explain the morbidity of CFS”. Geographically HHV-6 is not spread ideally uniformly; however, it is very common – in [5] we read that “more than 90% of children experience HHV-6B infection early in life” and after that HHV-6 stays latent for the life of the host.

The list of potential causes resulting in fatigue accompanying the SARS-CoV-2 infection includes: weakening from the fight against the disease, inflammation process, partial destruction of circulatory or nervous systems, psychological distress. But most frequently one would hear from experts that none of the listed causes has been proven until now. In conclusion then, I would like to pose a question open to a scientific debate: whether or not might the fatigue accompanying the SARS-CoV-2 infection be potentially co-evoked by the HHV-6 virus while the SARS-CoV-2 played the trigger role in its reactivation from the latent state?

References:

  1. COVID Symptom Study Sweden, accessed online on 30th Dec 2020 via https://csss-resultat.shinyapps.io/csss_dashboard/
  2. Nehme M, Braillard O, Alcoba G, et al. COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient Settings. Ann Intern. Med. 8th Dec 2020 https://doi.org/10.7326/M20-5926.
  3. Townsend L, Dyer AH, Jones K, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLOS ONE. 2020; 15(11) https://doi.org/10.1371/journal.pone.0240784
  4. Eymard D, Lebel F, Miller M, et al. Human Herpesvirus 6 and Chronic Fatigue Syndrome. Can J Infect Dis Med Microbiol. 1993; 4 https://doi.org/10.1155/1993/414602
  5. Jesse H. Arbuckle, Maria M. Medveczky, Janos Luka, et al. The latent human herpesvirus-6A genome specifically integrates in telomeres of human chromosomes in vivo and in vitro. PNAS. 2010; 107(12) https://doi.org/pnas.0913586107

Information & Authors

Information

Published In

cover image Annals of Internal Medicine
Annals of Internal Medicine
Volume 174Number 5May 2021
Pages: 723 - 725

History

Published online: 8 December 2020
Published in issue: May 2021

Keywords

Authors

Affiliations

Geneva University Hospitals, Geneva, Switzerland
Geneva University Hospitals, Geneva, Switzerland
Geneva University Hospitals and Médecins Sans Frontières, Geneva, Switzerland
Sigiriya Aebischer Perone, MD
Geneva University Hospitals and International Committee of the Red Cross, Geneva, Switzerland
Delphine Courvoisier, PhD https://orcid.org/0000-0002-1956-2607
Geneva University Hospitals, Geneva, Switzerland
François Chappuis, MD, PhD https://orcid.org/0000-0003-0442-7610
Geneva University Hospitals and University of Geneva, Geneva, Switzerland
Idris Guessous, MD, PhD
Geneva University Hospitals and University of Geneva, Geneva, Switzerland
for the COVICARE TEAM†
* Drs. Nehme and Braillard contributed equally to this work.
† For members of the COVICARE TEAM, see the Appendix.
Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-5926.
Reproducible Research Statement: Study protocol and statistical code: Available from Dr. Nehme (e-mail, [email protected]). Data set: Available from Dr. Nehme (e-mail, [email protected]). Data are made available upon agreement of the data provider and signature of a data transfer agreement.
Corresponding Author: Mayssam Nehme, MD, Rue Gabrielle-Perret-Gentil 4, 1211 Geneva, Switzerland; e-mail, [email protected].
This article was published at Annals.org on 8 December 2020.

Metrics & Citations

Metrics

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format





Download article citation data for:
Mayssam Nehme, Olivia Braillard, Gabriel Alcoba, et al; for the COVICARE TEAM†. COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient Settings. Ann Intern Med.2021;174:723-725. [Epub 8 December 2020]. doi:10.7326/M20-5926

View More

Get Access

Login Options:
Purchase

You will be redirected to acponline.org to sign-in to Annals to complete your purchase.

Create your Free Account

You will be redirected to acponline.org to create an account that will provide access to Annals.

View options

PDF/ePub

View PDF/ePub

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media